ERAS

Erasca, Inc.

A clinical-stage biopharmaceutical company developing medicines for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling routes in human tumors. Founded in San Diego in 2018, its name blends "RAS" with "era," reflecting a mission to open a new era in treating RAS-driven cancers. The company is building a pipeline of experimental drugs aimed at this stubborn family of cancer-causing proteins.

Recent Activity

Show $

2026Q2

1 buy

ArrowMark PartnersADD

+131.9K shares(+166.8%)

ArrowMark PartnersADD

+131.9K shares(+166.8%)

2026Q1

1 buy

ArrowMark PartnersNEW

+79.1K shares

ArrowMark PartnersNEW

+79.1K shares

Loading more activity...